Design, Synthesis and Biological Studies of Tetrazole Fused olpidemimidazopyridines
Document Type
Peer-Reviewed Article
Publication Date
2023
Abstract
New tetrazole fused imidazopyridine derivatives (12a–j) were developed to exploit their cytotoxic activity towards cancer cell lines-MCF7, A549, and MDA-MB-231, utilizing MTT reduction assay with doxorubicin as standard drug. The compounds 12 h and 12j demonstrated strong anticancer activity bearing IC50 values 1.44 µM and 1.33 µM against A549 cell line.
DOI
10.1007/s42823-023-00603-2
Recommended Citation
Reddy, B., Taneja, A. K., Tej, M. B., Sri, K. N., Tej, M. B., Vijayardhini, S., Srilaxmi, D., Tiruveedhula, S., Penumutchu, S. R., & Rao, M. V. B. (2023). Design, synthesis and biological studies of tetrazole fused imidazopyridines. Carbon Letters. https://doi.org/10.1007/s42823-023-00603-2
Comments
Published: 11 September 2023.